Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

TitleDelaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.
Publication TypeJournal Article
Year of Publication2009
AuthorsTenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, Deeks SG, Landay AL, Riddler SA
JournalAIDS Res Hum Retroviruses
Volume25
Issue2
Pagination135-9
Date Published2009 Feb
ISSN1931-8405
KeywordsAcquired Immunodeficiency Syndrome, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Candida, CD4 Lymphocyte Count, Cell Proliferation, Drug Resistance, Viral, HIV-1, Humans, Mycobacterium avium Complex, RNA, Viral, Viral Load
Abstract

Some patients are unable to achieve and maintain an undetectable plasma HIV-1 RNA level with combination antiretroviral therapy (ART) and are therefore maintained on a partially suppressive regimen. To determine the immune consequences of continuing ART despite persistent viremia, we randomized 47 ART-treated individuals with low to moderate plasma HIV-1 RNA levels (200-9999 copies/ml) to either an immediate switch in therapy or a delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml). After 48 weeks of follow-up, naive and memory CD4+ T cell percents were comparable in the two groups. The proportion of subjects with a lymphocyte proliferative response to Candida, Mycobacterium avium-intracellulare complex, or HIV-gag was also not significantly different at week 48. Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters.

DOI10.1089/aid.2008.0200
Alternate JournalAIDS Res. Hum. Retroviruses
PubMed ID19239354
PubMed Central IDPMC2755543
Grant ListAI 068636 / AI / NIAID NIH HHS / United States
AI 68636 / AI / NIAID NIH HHS / United States
K24 AI001744 / AI / NIAID NIH HHS / United States
K24 AI001744-01 / AI / NIAID NIH HHS / United States
K24 AI001744-05 / AI / NIAID NIH HHS / United States
K24 RR 16482 / RR / NCRR NIH HHS / United States
K24 RR016482 / RR / NCRR NIH HHS / United States
K24 RR016482-01 / RR / NCRR NIH HHS / United States
P30 AI 64518 / AI / NIAID NIH HHS / United States
P30 AI064518 / AI / NIAID NIH HHS / United States
P30 AI064518-049005 / AI / NIAID NIH HHS / United States
U01 AI 062563 / AI / NIAID NIH HHS / United States
U01 AI 068634 / AI / NIAID NIH HHS / United States
U01 AI 069471 / AI / NIAID NIH HHS / United States
U01 AI 069472 / AI / NIAID NIH HHS / United States
U01 AI 069484 / AI / NIAID NIH HHS / United States
U01 AI 069494 / AI / NIAID NIH HHS / United States
U01 AI 38855 / AI / NIAID NIH HHS / United States
U01 AI038858 / AI / NIAID NIH HHS / United States
U01 AI038858-059001 / AI / NIAID NIH HHS / United States
U01 AI062563 / AI / NIAID NIH HHS / United States
U01 AI062563-04 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068634-01 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636-01 / AI / NIAID NIH HHS / United States
U01 AI069471 / AI / NIAID NIH HHS / United States
U01 AI069471-01 / AI / NIAID NIH HHS / United States
U01 AI069484 / AI / NIAID NIH HHS / United States
U01 AI069484-02 / AI / NIAID NIH HHS / United States
U01 AI069494 / AI / NIAID NIH HHS / United States
U01 AI069494-01 / AI / NIAID NIH HHS / United States